purpose. The boron concentration in tumors depends on tumor characteristics, including the expression level of transporters and tumor vascularity; thus, the pharmacokinetics of BPA should be determined in individual patients. To estimate BPA accumulation and the T/N ratios, PET using 4-borono-2- 18 F-fluoro-phenylalanine ( 18 F-FBPA PET) has been performed. [3] [4] [5] [6] [7] Previously, we reported that 18 F-FBPA was predominantly transported by L-type amino acid transporter (system L). 8 In rat 9L gliosarcoma cells, 2-aminobicyclo-(2.2.1)-heptane-2-carboxylic acid (BCH) inhibited BPA uptake, which suggested that system L played a role in this phenomenon. 9 However, the transport and uptake of 18 F-FBPA have not been compared with those of BPA in detail.
In addition, there are 2 differences between 18 F-FBPA in PET and BPA in BNCT. First, the administration dose of BPA is 250-500 mg/kg compared with tracer doses of 18 F-FBPA in PET. 10, 11 Second, BPA is administrated via continuous intravenous infusion (CIV), whereas 18 F-FBPA is administrated via bolus injection. Owing to the difficulty of excising tumor tissue samples from patients with glioblastoma for evaluation of boron concentration in tumor tissues, it remains unclear whether tumor uptake of 18 F-FBPA is associated with that of BPA.
The present study verified whether the transport mechanism of 18 F-FBPA is identical to that of BPA. Subsequently, we determined the tumor uptake of 18 F-FBPA and BPA in human tumor xenograft models. The present study also investigated the utility of Cultures (Salisbury, UK). All cells were cultured according to the suppliers' protocols and were maintained in a humidified atmosphere of 5% CO 2 in air at 37°C. Six human tumor xenograft models were used in the biodistribution and small animal PET/computed tomography (CT) studies. Female BALB/c nude mice and female SCID mice (4-5 weeks old) were obtained from CLEA Japan (Tokyo, Japan).
Prior to the experiments, the mice were acclimatized for ≥1 week. PET/CT images were obtained using a small animal PET/CT scan- 
| Boron evaluation in tumor-bearing mice
A total of 250 lL BPA (250 mg/kg body weight) was injected via the tail vein at a rate of 8.33 lL/min for 30 minutes using the syringe pump. The mice were sacrificed 1 hour after initiation of BPA injection, and the blood, brain and tumor were excised. The tissue samples were digested with perchloric acid and hydrogen peroxide (2:1) at 75°C. The boron concentrations in each sample were evaluated by inductively coupled plasma-atomic emission spectrometry (SPS3500DD; SII Nanotechnology, Tokyo, Japan), and were normalized as ppm.
| Statistical analysis
Results are expressed as the mean AE SD. Statistical analysis was The CIV with BPA showed similar time-activity curves with the CIV ( Figure 4F ). 18 F-FBPA uptake in the heart, kidney and liver con- LAT1, LAT2, LAT3 and LAT4 isoforms of system L have previously been identified. [14] [15] [16] [17] Western blot analysis in this study suggests that LAT1 may predominantly contribute to An advantage of CIV in animal studies is that it can be used to reproduce human pharmacokinetics of BPA. In particular, BPA concentration in the blood may affect its tissue distribution. Boron concentration in the blood continued to increase during infusion in a previous clinical study. 10 In our PET analysis, CIV of 18 F-FBPA also showed a continuous increase of uptake in the heart, suggesting an increase in the blood concentration of 18 F-FBPA. In previous animal studies, BPA has been intraperitoneally administered due to the ease of the experimental procedure. [23] [24] [25] [26] [27] However, the pattern of increase in the blood remains unknown, and it is difficult to control blood concentration by intraperitoneal injection.
Our animal studies demonstrated that In conclusion, this study demonstrated that tumor uptake of 
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